Os Fatores de Crescimento de Fibroblastos (\"Fibroblast Growth Factors\"; FGFs) participam de fenômenos biológicos de grande importância, tais como migração, divisão e diferenciação celulares. O presente trabalho teve como objetivo central a busca de compostos biologicamente ativos através de um desenho racional de peptídeos derivados do FGF-1 e do seu receptor (FGFR-1 ). A partir da análise dos dados disponíveis na literatura, aliada a técnicas de modelagem molecular, foram desenhados, sintetizados e testados dois grupos de peptídeos. O primeiro conjunto (R1 - R3) é constituído por peptídeos lineares derivados do FGFR-1. Os ensaios de atividade mitogênica dos FGFs 1 e 2 em presença dos peptídeos mostram que R1 e R2 foram capazes de inibir a ação mitogênica do FGF-1. Este efeito é seletivo, já que a atividade do FGF-2 não é afetada. A atividade inibitória é dose-dependente para ambos os peptídeos. Os resultados mostram ainda que o efeito é sequência-dependente, já que o peptídeo R3, correspondente à porção e-terminal de R2, é inativo. Por outro lado, o segmento N-terminal de R2 (representado por R1) é suficiente para desencadear o mesmo nível de inibição apresentado pelo peptídeo R2 inteiro. Os peptídeos sintéticos semi-cíclicos F1 - F3, correspondentes a um importante sítio de ligação no FGF-1, foram avaliados quanto à sua capacidade de estimular a síntese de DNA em fibroblastos em cultura. Os dados obtidos mostram que, na faixa de concentração testada (0,1 a 200 µM), o peptídeo F1 é inativo. O peptídeo F2 apresentou atividade mitogênica (ED50 = 60 -70 µM), estimulando a incorporação de timidina tritiada em até 66 % do valor máximo induzido por 10% de soro fetal bovino. Na mesma faixa de concentração, o peptídeo F3 apresentou atividade em níveis inferiores (ED50 > 100 µM) aos apresentados pelo peptídeo F2. Estes resultados indicam que os peptídeos F2 e F3 poderiam mimetizar a superfície correspondente a um sítio de ligação do FGF-1 ao receptor. Além disso, o fato de F2 ser mais ativo que F3 indica que, além dos resíduos hidrofóbicos Y e L (presentes em ambos), o resíduo R presente em F2 exerce um importante papel para a atividade mitogênica do peptídeo. Como já proposto por nós em trabalhos anteriores, os dados apresentados indicam que é possível obter compostos com atividade mitogênica através do desenho racional de estruturas peptídicas derivadas dos FGFs. A análise do conjunto de peptídeos estudados até o momento revela a existência de características químicas comuns a todos aqueles que se mostraram mitogênicos, ou seja, a presença de um núcleo hidrofóbico flanqueado por resíduos polares carregados. / The Fibroblast Growth Factors (FGFs) are involved in very important biological processes like cell migration, division and differentiation. The aim of this work was the search of biologically active compounds through a rational design of peptides derived from FGF-1 and its receptor (FGFR-1). On the basis on several data available in the literature and with the aid of molecular modeling techniques, we designed, synthesized and tested two sets of peptides. The first group (R1-R3) is composed by linear peptides derived from FGFR-1. The mitogenic activity assays of FGF-1 and FGF-2 in the presence of these peptides reveal that R1 and R2 were able to inhibit the mitogenic response elicited by FGF-1. This effect is dose-dependent and selective, since the FGF-2 activity was not affected. Also, the inhibitory activity is sequence-dependent since peptide R3, corresponding to the e-terminal stretch of R2, was inactive. On the other hand, the N-terminal segment of peptide R2, represented by R1, is sufficient to elicit about the same response observed for the longer peptide R2. The semi-cyclic synthetic peptides F1 - F3, corresponding to an important FGF-1 binding site, were tested for their ability to stimulate DNA synthesis on fibroblast cultures. The results show that F1 is inactive in the range tested (0.1 to 200 µM). Peptide F2 was able to elicit a mitogenic activity (ED50 = 60 - 70 µM), stimulating the incorporation of [methyl-3H] thymidine to a level corresponding to 66 % of the maximum response induced by 10 % fetal calf serum. In the same range, peptide F3 was less active (ED50 > 100 µM). These results suggest that peptides F2 and F3 could mimic a surface corresponding to a receptor binding site of FGF-1. Also, the better performance of F2 could be explained by the presence of the residue R (besides Y and L) that could be important to elicit a mitogenic response. These results, together with those presented in former papers, indicate that it is possible to obtain compounds with mitogenic activity through the rational design of peptides derived from the FGFs. The analysis of the assembly of peptides studied allow us to define a chemical pattern shared by all the mitogenic compounds obtained until now, namely the presence of a hydrophobic core flanked by polar charged residues.

Descrevemos, recentemente, que FGF2 parácrino dispara senescência nas linhagens celulares murinas Y1 e 3T3-B61, transformadas malignamente por Ras, mas sem ativação das vias apoptóticas (Costa et al., 2008). Nesta tese, estudamos os mecanismos celulares e moleculares desta resposta de estresse irreversível, disparada por FGF2. Focalizamos, principalmente, a linhagem Y1, que carrega uma amplificação do oncogene Kras, mas apresenta um controle parcial da transição G0/G1 → S do ciclo celular. Por estas características fenotípicas, as células Y1 foram utilizadas no estudo dos mecanismos das ações antagônicas de FGF2, isto é, a atividade mitogênica clássica e a nova ação citotóxica que causa senescência. Análises de citometria de fluxo e marcação com BrdU mostraram que FGF2 promove a transição G0/G1 → S (atividade mitogênica), mas bloqueia a progressão através de S e G2/M (atividade antimitogênica). Ensaios de viabilidade celular (MTS e Cyto-Tox) demonstraram que, durante o bloqueio do ciclo celular por FGF2, as células permanecem íntegras e metabolicamente ativas, embora exibam alterações morfológicas, que sugerem estresse celular. Além disso, experimentos de tomada de 3H-timidina em DNA evidenciaram que, já nas primeiras horas de G1, FGF2 dispara um processo antimitogênico que só tardiamente vai se manifestar na fase S, bloqueando a síntese de DNA. Verificamos ainda, que o inibidor específico da Tyr-quinase dos receptores de FGF, PD173074, abole completamente, tanto os efeitos mitogênicos como os antimitogênicos de FGF2 nas células Y1, demonstrando que ambos os processos iniciam-se com a ativação da Tyr-quinase dos FGFRs. Por outro lado, inibidores específicos das vias de sinalização de MEK/ERK, PI3K/AKT e PKC (todas mitogênicas e à jusante dos FGFRs) bloqueiam a progressão no ciclo celular, sem proteger as células Y1 de FGF2, evidenciando que estas vias mitogênicas não participam dos mecanismos moleculares citotóxicos disparados por FGF2. Entretanto, inibidores das Tyr-quinases Src protegem parcialmente as células Y1 de FGF2, implicando a família Src na transformação maligna destas células. Para buscar novos genes pertinentes à ação citotóxica de FGF2 analisamos expressão gênica por RT-qPCR, dando continuidade a estudos anteriores desenvolvidos no laboratório, através de microarranjos de cDNA (Asprino & Armelin, 2006). Desta busca, resultaram genes codificantes de proteínas envolvidas no controle de ciclo celular, adesão e citoesqueleto, com destaque para proteínas reguladoras de RhoGTPases e os receptores de FGF. Procuramos também examinar especificidades entre os FGFRs, quanto ao disparo das ações antagônicas de FGF2. As células Y1 expressam FGFR1IIIc, FGFR2IIIc e FGFR5 enquanto as 3T3-B61 expressam FGFR1IIIc e FGFR5. A redução da expressão de FGFR2 por RNAi, em células Y1, não impediu a ação citotóxica de FGF2, mas a redução de FGFR1 protegeu as células da ação morfológico-estressante de FGF2. Como FGFR5 não possui domínio de Tyr-quinase, concluímos que o FGFR1 é o receptor mais relevante para o efeito citotóxico de FGF2, em ambas as células. Em conclusão, FGF2 ativa a Tyr-quinase dos FGFRs, disparando mecanismos moleculares antagônicos, paralelos e independentes, onde o efeito final é o bloqueio do ciclo celular nas fases S e G2/M e, consequentemente, senescência celular. / We have recently described that paracrine FGF2 triggers senescence in Ras-driven murine cell lines Y1 and 3T3-B61, without activation of apoptotic pathways (Costa et al., 2008). On this thesis, we studied the molecular and cellular mechanisms of this irreversible stress response triggered by FGF2. We have mainly focused on the Y1 cell line, which carries Kras oncogene amplification, but presents a certain control of the G0/G1 → S cell cycle transition. Because of these phenotypic features, the Y1 cells were utilized to study the mechanisms of FGF2 antagonic actions, i. e., the classical mitogenic activity and the new cytotoxic action, which causes senescence. Flow cytometer analysis and BrdU labeling have shown that FGF2 promotes the G0/G1 → S transition (mitogenic activity), but arrests the progression through S and G2/M (antimitogenic activity). Viability assays (MTS and Cyto-Tox) have shown that, during the cell cycle arrest by FGF2, cells remain intact and metabolically active, although exhibiting morphologic alterations, which suggested cellular stress. Moreover, 3H-thymidine uptake into DNA has evidenced that, within the first hours of G1, FGF2 triggers an antimitogenic process that only lately will manifest in S phase, blocking DNA synthesis. We have further verified that the specific Tyr-kinase inhibitor, PD173074, completely abolishes both FGF2 mitogenic and antimitogenic effects, showing that both processes start at FGFRs Tyr-kinase. On the other hand, specific inhibitors of MEK/ERK, PI3K/AKT and PKC signaling pathways (all mitogenic and downstream of FGFRs) block the cell cycle progression, but do not protect cells from FGF2, showing that these pathways do not participate of the cytotoxic molecular mechanisms triggered by FGF2. However, Src Tyr-kinases inhibitors partially protect Y1 cells from FGF2, implicating the Src family on malignant transformation of these cells. To search new genes pertinent to the cytotoxic action of FGF2, we analyzed gene expression by RT-qPCR, continuing previous studies developed in our laboratory through cDNA microarrays (Asprino & Armelin, 2006). This search revealed protein-coding genes involved on cell cycle control, cellular adhesion and cytoskeleton, in which we highlighted regulatory proteins of RhoGTPases and FGF receptors. We also examined specificities among FGFRs in relation to FGF2 antagonic actions. Y1 cells express FGFR1IIIc, FGFR2IIIc and FGFR5 whereas 3T3-B61 cells express FGFR1IIIc and FGFR5. In Y1 cells, the knockdown of FGFR2 expression by RNAi do not stop FGF2 cytotoxic actions, but knockdown of FGFR1 expression protects cells from the FGF2 morphologic-stressing action. Since FGFR5 lacks Tyr-kinase domain, we concluded that FGFR1 is the most relevant receptor for FGF2 cytotoxic effect in both cells. In conclusion, FGF2 activates FGFRs Tyr-kinase, triggering parallel and independent antagonic molecular mechanisms, in which the final effect is the S and G2/M cell cycle arrest and, consequently, cellular senescence.

<p>Human physiology is dependent on an accurate phosphate (Pi) homeostasis. Defective Pi regulation causes hyper- or hypophosphatemia, which are associated with ectopic calcification or impaired bone mineralization, and a shortened life span. Current endocrine models of Pi homeostasis are incomplete. However, studies of acquired and hereditary disorders of Pi homeostasis have revealed new potential Pi regulating hormones, Phosphatonin(s). One of these is fibroblast growth factor-23 (FGF23). FGF23 is produced in bone and is secreted into the circulation. Mutations in FGF23 causes disturbed Pi regulation, without the appropriate counter-regulatory actions of parathyroid hormone or vitamin D. By the generation of FGF23 transgenic mice, which display phenotypic similarities to patients with hypophosphatemic disorders, we show that FGF23 exerts endocrine actions in the kidney and causes osteomalacia. Renal FGF23 actions severely decrease Pi reabsorption and expression of Klotho, a suggested age suppressor gene, known to be crucial in FGF23 receptor binding and activation. In bone, our transgenic model displays impaired osteoclast polarization, which should be detrimental to osteoclastic bone resorption in osteomalacia. However, in our model osteoclasts efficiently participate in bone matrix degradation. Furthermore, we investigated a large population-based cohort in order to elucidate the role of FGF23 in normal physiology. Importantly, we were able to demonstrate an association of FGF23 to parathyroid hormone, renal function and bone mineral density and we found a correlation of FGF23 to weight and body fat mass. The studies on which this thesis is based, demonstrate that FGF23 has phosphatonin-like properties and that the skeleton functions as an endocrine organ. In addition, the results indicate that FGF23 has a role in bone mineral and lipid metabolism, and that FGF23 is a possible diagnostic marker and therapeutic target for the future.</p>

The mature mammalian brain continually generates new neurons in the subventricular zone and hippocampus throughout life. Adult neurogenesis in the hippocampus is associated with hippocampal-dependent learning and memory function. During aging, this endogenous neurogenic potential is reduced which is accompanied by decreased cognitive function seen in the aging population. We have previously found that the injured adult brain shows heightened levels of endogenous neurogenesis and this response is associated with innate cognitive recovery. We have also found that basic fibroblast growth factor (bFGF), a potent neurotrophic polypeptide, can enhance injury-induced hippocampal neurogenesis and improve cognitive recovery following TBI. In this study, we administered bFGF into the lateral ventricle of aged rats following TBI and assessed the effect of bFGF treatment on hippocampal neurogenesis and cognitive recovery in aged animals. Specifically, male Fisher-344 rats at the age of 20 months received intraventricular infusion of bFGF for 7 days through osmotic mini-pump immediately following a moderate lateral fluid percussion injury. To label cell proliferation, animals received daily single i.p. BrdU injections for 6 days beginning 48 hr after injury. One group of animals was perfused at 1 wk after injury to assess cell proliferation. Another group of animals was first assessed for cognitive performance using the Morris water maze (MWM) at 21-25 days post-injury, then sacrificed at 4 weeks after injury to examine differentiation of newly generated cells. Brain sections were sliced and immunostained for BrdU, early neuronal marker doublecortin (DCX) and other cell type specific markers. Results showed that at 1 week post-injury, injured-aged animals infused with either vehicle or bFGF had a significantly higher number of cell proliferation in the dentate gyrus compared to sham animals. However, cell proliferation in the bFGF-infused animals was not significantly higher than vehicle-treated animals. Nevertheless, the number of DCX-labeled early stage neurons was significantly higher in the injured bFGF-treated animals than in vehicle-treated sham and injured animals. In MWM tests, unlike what we have observed in bFGF-treated younger animals, injured aged rats treated with bFGF did not show improved cognitive function. Furthermore, at 4 weeks post-injury, higher numbers of BrdU-labeled proliferative cells persisted in both injured groups, many of these cells labeled with glial and inflammatory cell markers. Collectively, the current data suggests that bFGF can enhance neurogenesis in the injured-aged hippocampus; however, this effect is not sufficient to improve functional recovery of aged rats following TBI due to the profound injury-induced inflammatory response.

Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

No description available.

<p>Fibroblast growth factors (FGFs) constitute a family (currently FGF-1 to FGF-23) of polypeptides that are essential in embryonal development and adult physiology, in animals from nematodes to humans. FGFs bind to four receptor tyrosine kinases, denoted FGFR-1 to FGFR-4. For proper function, the FGFs and their receptors depend on specific polysaccharide co-receptors, denoted heparan sulfate (HS). This thesis describes HS regulation of FGFR-1 signal transduction using blood vessel endothelial cells as a model.</p><p>We have determined HS structural features, necessary for FGF-2 induced FGFR-1 activation, using chemically modified heparin, which is structurally related to HS. Modified heparin, lacking sulfation at the 6-O position was inhibitory for FGFR-1 kinase activation and FGF-2 induced angiogenesis. Inhibition of blood vessel formation using modified heparin could be useful in treatment of diseases characterized by excess blood vessel formation. The critical role of HS sulfation for proper growth factor function was further underscored using an embryonal stem (ES) cell model. ES cells lacking expression of two isoforms of N-deacetyl N-sulfotransferase, NDST-1 and –2, failed to undergo embryonal development and to establish a vascular system. Exogenous heparin could not support development, but HS delivered from other ES cells allowed formation of primitive vessels and subsequent sprouting angiogenesis.</p><p>We have, furthermore, shown that the mechanism whereby HS supports FGF receptor activation is qualitative, as well as quantitative. Kinase activity could be induced by FGF-2 in the absence of HS, but this allowed only selected phosphorylation. In the presence of HS, the kinase activity was stabilized, allowing a broader spectrum of phosphorylation of sites on the FGF receptor itself as well as on cytoplasmic substrates. Finally, using selected microarrays, we have examined the potential regulation of enzymes in the HS biosynthesis pathway and of different proteoglycans to which HS is attached. Overall, we found no evidence for dramatic regulation on the transcriptional level, but could identify specific upregulation of HS proteoglycan syndecan-2, during blood vessel formation in vitro.</p><p>In conclusion, our studies demonstrate selective and complex regulation of HS synthesis and structure, essential in guiding growth factor function during health and disease.</p>

<p>During development of the mammalian embryo, spatial and temporal expression of fibroblast growth factors (FGFs) and their cognate receptors are vital in the regulation of a number of patterning processes. Inappropriate or decreased expression leads to severe malformations and even embryonic death. The objectives of this thesis have been to evaluate the usefulness of differentiating embryonic stem (ES) cells as a model to study FGF and FGF receptors in endothelial and hematopoietic cell function in vitro and in vivo, and the effect of an activating mutation in the platelet-derived growth factor receptor-β (PDGFR-β) on endothelial cells and vessel formation.</p><p>Aggregates of differentiating ES cells, denoted embryoid bodies, faithfully recapitulate many developmental processes. Embryoid bodies cultured in fetal calf serum spontaneously develop cardiomyocytes and endothelial cells. The endothelial cells organize into lumen-containing vessels carrying erythroblasts. Administration of FGF or vascular endothelial growth factor (VEGF)-A promotes development of specific vascular phenotypes. About 20% of endothelial cells in embryoid bodies and teratomas express FGFR-1, and these FGFR-1-expressing endothelial cells are mitogenically active in the absence of exogenous stimuli and respond to VEGF-A to the same extent as endothelial cells lacking FGFR-1 expression. FGFR-1 deficiency leads to arrest in hematopoietic differentiation, whereas endothelial cell development is enhanced. As a consequence, teratomas derived from ES cells lacking FGFR-1 expression display vessels composed of a double layer of endothelial cells. The hyperactivity of endothelial cells derived from FGFR-1-deficient ES cells is suggested to be due to hyperactivity of VEGF receptor-2, as well as to loss of negative regulators of angiogenesis, such as interleukin-4.</p><p>Mutation of platelet-derived factor receptor-β (PDGFR-β) to replace D849 in the activating loop in the kinase domain with V leads to ligand-independent kinase activity, increased basal signal transduction, and enhanced expression of VEGF-A as well as VEGFR-2. As a result, endothelial cell sprouts covered with pericyte-like cells are formed in a VEGF-A/VEGFR-2 dependent manner in ES cells expressing the mutated PDGFR-β.</p><p>In conclusion, embryoid bodies represent a high-quality model for the study of growth factor-regulated vascular development and sprouting angiogenesis.</p>

Fibroblast growth factors (FGFs) constitute a family (currently FGF-1 to FGF-23) of polypeptides that are essential in embryonal development and adult physiology, in animals from nematodes to humans. FGFs bind to four receptor tyrosine kinases, denoted FGFR-1 to FGFR-4. For proper function, the FGFs and their receptors depend on specific polysaccharide co-receptors, denoted heparan sulfate (HS). This thesis describes HS regulation of FGFR-1 signal transduction using blood vessel endothelial cells as a model. We have determined HS structural features, necessary for FGF-2 induced FGFR-1 activation, using chemically modified heparin, which is structurally related to HS. Modified heparin, lacking sulfation at the 6-O position was inhibitory for FGFR-1 kinase activation and FGF-2 induced angiogenesis. Inhibition of blood vessel formation using modified heparin could be useful in treatment of diseases characterized by excess blood vessel formation. The critical role of HS sulfation for proper growth factor function was further underscored using an embryonal stem (ES) cell model. ES cells lacking expression of two isoforms of N-deacetyl N-sulfotransferase, NDST-1 and –2, failed to undergo embryonal development and to establish a vascular system. Exogenous heparin could not support development, but HS delivered from other ES cells allowed formation of primitive vessels and subsequent sprouting angiogenesis. We have, furthermore, shown that the mechanism whereby HS supports FGF receptor activation is qualitative, as well as quantitative. Kinase activity could be induced by FGF-2 in the absence of HS, but this allowed only selected phosphorylation. In the presence of HS, the kinase activity was stabilized, allowing a broader spectrum of phosphorylation of sites on the FGF receptor itself as well as on cytoplasmic substrates. Finally, using selected microarrays, we have examined the potential regulation of enzymes in the HS biosynthesis pathway and of different proteoglycans to which HS is attached. Overall, we found no evidence for dramatic regulation on the transcriptional level, but could identify specific upregulation of HS proteoglycan syndecan-2, during blood vessel formation in vitro. In conclusion, our studies demonstrate selective and complex regulation of HS synthesis and structure, essential in guiding growth factor function during health and disease.

During development of the mammalian embryo, spatial and temporal expression of fibroblast growth factors (FGFs) and their cognate receptors are vital in the regulation of a number of patterning processes. Inappropriate or decreased expression leads to severe malformations and even embryonic death. The objectives of this thesis have been to evaluate the usefulness of differentiating embryonic stem (ES) cells as a model to study FGF and FGF receptors in endothelial and hematopoietic cell function in vitro and in vivo, and the effect of an activating mutation in the platelet-derived growth factor receptor-β (PDGFR-β) on endothelial cells and vessel formation. Aggregates of differentiating ES cells, denoted embryoid bodies, faithfully recapitulate many developmental processes. Embryoid bodies cultured in fetal calf serum spontaneously develop cardiomyocytes and endothelial cells. The endothelial cells organize into lumen-containing vessels carrying erythroblasts. Administration of FGF or vascular endothelial growth factor (VEGF)-A promotes development of specific vascular phenotypes. About 20% of endothelial cells in embryoid bodies and teratomas express FGFR-1, and these FGFR-1-expressing endothelial cells are mitogenically active in the absence of exogenous stimuli and respond to VEGF-A to the same extent as endothelial cells lacking FGFR-1 expression. FGFR-1 deficiency leads to arrest in hematopoietic differentiation, whereas endothelial cell development is enhanced. As a consequence, teratomas derived from ES cells lacking FGFR-1 expression display vessels composed of a double layer of endothelial cells. The hyperactivity of endothelial cells derived from FGFR-1-deficient ES cells is suggested to be due to hyperactivity of VEGF receptor-2, as well as to loss of negative regulators of angiogenesis, such as interleukin-4. Mutation of platelet-derived factor receptor-β (PDGFR-β) to replace D849 in the activating loop in the kinase domain with V leads to ligand-independent kinase activity, increased basal signal transduction, and enhanced expression of VEGF-A as well as VEGFR-2. As a result, endothelial cell sprouts covered with pericyte-like cells are formed in a VEGF-A/VEGFR-2 dependent manner in ES cells expressing the mutated PDGFR-β. In conclusion, embryoid bodies represent a high-quality model for the study of growth factor-regulated vascular development and sprouting angiogenesis.